Active Stocks
Fri Apr 12 2024 15:57:45
  1. Tata Steel share price
  2. 163.50 -1.00%
  1. NTPC share price
  2. 362.00 -0.32%
  1. ITC share price
  2. 430.10 -1.56%
  1. HDFC Bank share price
  2. 1,518.90 -1.10%
  1. State Bank Of India share price
  2. 766.75 -1.57%
Business News/ Markets / Stock Markets/  Stocks to buy: Biocon, Dr Reddy’s, Sun Pharma, among Phillip Capital’s pharma stock picks for up to 22% upside
BackBack

Stocks to buy: Biocon, Dr Reddy’s, Sun Pharma, among Phillip Capital’s pharma stock picks for up to 22% upside

Phillip Capital estimates pharma companies under its coverage to report 12% YoY earnings growth on account of 40 bps expansion in EBITDA margins and 15% sales growth in Q2.

Phillip Capital has Buy ratings on Biocon, Zydus LifeSciences, Dr Reddy’s Laboratories and Sun Pharmaceutical Industries ahead of Q2 resultsPremium
Phillip Capital has Buy ratings on Biocon, Zydus LifeSciences, Dr Reddy’s Laboratories and Sun Pharmaceutical Industries ahead of Q2 results

Indian Pharma Industry is set to gain from the continuing benefits from gRevlimid as well as easing price pressure in the US generics market, softening input, freight and energy cost and rupee depreciation amid the moderating domestic formulations. 

Phillip Capital estimates pharma companies under its coverage to report 12% YoY earnings growth on account of 40 bps expansion in EBITDA margins and 15% sales growth in Q2. 

While the US generic price pressure eased sequentially, the incremental benefits from key launches and 4% INR depreciation YoY complements US generics growth. 

Moreover, after seeing consistent double-digit growth in the branded formulations business over last years, the industry is continuing its moderated growth trend of Q1 into performance in Q2 despite the advantage of price rise YoY. Therapies like Cardiac, Derma, pain management saw >6% YoY growth, while respiratory turned weak after a strong growth in the recent months, as per Phillip Capital.

Phillip Capital has Buy ratings on these pharma stocks:

Biocon | Buy | TP: 310

Phillip Capital expects Biocon’s sales to grow 58% mainly led by the integration of acquired biosimilars operation of Viatris as well as sequential improvement in Fulphila/Semglee penetration in the US. It sees strong 28% growth in research services led by ramp up in CDMO and steady growth in small molecules. 

The company’s margins may expand 350 bps to 23.8% led by the integration advantage, improving biosimilars sales and improving margins in research services, the brokerage said.

It has a ‘Buy’ rating on the stock with a target price of 310 per share, implying an upside of 21% from Friday’s closing price.

(Exciting news! Mint is now on WhatsApp Channels :rocket: Subscribe today by clicking the link and stay updated with the latest financial insights! Click here!)

Zydus LifeSciences | Buy | TP: 725

With continued gRevlimid benefit, Q2 earnings of the company are expected to remain strong with 44% YoY growth. Margins are likely to improve 740 bps YoY on a low base and incremental benefits of gRevlimid, leading to 65% jump in EBITDA. 

The brokerage gave a Buy call on Zydus LifeSciences with a target of 725 per share, expecting an upside of over 22% from Monday’s closing price.

Dr Reddy’s Laboratories | Buy | TP: 6,200

Dr Reddy’s Laboratories is estimated to see 5% rise in revenue on account of strong US sales at $355 million and 10% like to like growth in domestic formulations. Margins may correct 440 bps QoQ and 430 bps YoY mainly due to lower gRevlimid sales and product mix, leading to 8% fall in EBITDA.

Phillip Capital has a Buy call on the stock with a target of 6,200 per share, implying an upside of nearly 13% from Monday’s closing price.

Sun Pharmaceutical Industries | Buy | TP: 1,250

Sun Pharmaceutical Industries is expected to report 10% sales growth on account of continued gRevlimid sales ($40 million) and sustained growth in US specialty (+19%) as well as domestic formulations (+8%), despite muted Taro and impact of import alerts. Its margins are likely to correct 240 bps QoQ on account of lower R&D base and remediation charges.

The brokerage has a ‘Buy’ rating on the stock with a target price of 1,250 per share, expecting a 10% upside from previous close.

Catch Live Market Updates here

Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before taking any investment decisions.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Published: 17 Oct 2023, 10:17 AM IST
Next Story footLogo
Recommended For You
GENIE RECOMMENDS

Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!

Let’s get started
Switch to the Mint app for fast and personalized news - Get App